Overview

Europe Prostate Cancer Drugs Market Overview:

FutureWise Market Research has instantiated a report that provides an intricate analysis of Europe Prostate Cancer Drugs Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Europe Prostate Cancer Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Europe Prostate Cancer Drugs Market:
• GlaxoSmithKline
• AstraZeneca plc
• Johnson & Johnson
• Sanofi S.A
• Bayer AG
• Novartis
• Elekta
• Theragenics
• Pfizer Inc.
• Abbot Laboratories
• Genentech
• Roche
• AbbVie
• Varian Medical Systems
(Note: The list of the major players will be updated with the latest market scenario and trends)

Europe Prostate Cancer Drugs Market Segmentation:
By Type
• Hormone Sensitive Prostate Cancer
• Hormone Refractory Prostate Cancer

By Therapy
• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy

By End User
• Hospitals
• Clinics
• Others

By Region
• Germany
• U.K        
• France
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Europe Prostate Cancer Drugs Market By Type, By Therapy, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— Germany, U.K, France, Italy, Spain, Russia, Poland, Rest of Europe
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customisation offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Europe Prostate Cancer Drugs Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Product Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Europe Prostate Cancer Drugs Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Product Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Product Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Europe Prostate Cancer Drugs Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Hormone Sensitive Prostate Cancer
  7.2. Hormone Refractory Prostate Cancer

8. Europe Prostate Cancer Drugs Market, By Therapy Historical Analysis and Forecast 2020-2027 (USD Million)
  8.1. Hormonal Therapy
  8.2. Chemotherapy
  8.3. Immunotherapy
  8.4. Targeted Therapy
 
9. Europe Prostate Cancer Drugs Market, by End User Historical Analysis and Forecast 2020-2027 (USD Million)
  9.1. Hospitals
  9.2. Clinics
  9.3. Others

10. Europe Prostate Cancer Drugs Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         10.2.1. Germany
         10.2.2. U.K        
         10.2.3. France
         10.2.4. Italy
         10.2.5. Spain
         10.2.6. Russia
         10.2.7. Poland
         10.2.8. Rest of Europe
   10.3. Market Size (USD Million) Forecast for Europe 2020-2027

11. Market Share Analysis and Competitive Landscape  
   11.1. Europe Landscape - Key Players, Revenue and Presence
   11.2. Europe Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   11.3. Europe Emerging Companies
   11.4. Europe - Market Share Analysis and Key Regional Player
   11.5. Europe Key Player - Growth Matrix

12. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   12.1. GlaxoSmithKline
         12.1.1. Company Overview
         12.1.2. Product Portfolio
         12.1.3. SWOT Analysis
         12.1.4. Financial Overview
         12.1.5. Strategic Overview
   12.2. AstraZeneca plc
         12.2.1. Company Overview
         12.2.2. Product Portfolio
         12.2.3. SWOT Analysis
         12.2.4. Financial Overview
         12.2.5. Strategic Overview
   12.3. Johnson & Johnson
         12.3.1. Company Overview
         12.3.2. Product Portfolio
         12.3.3. SWOT Analysis
         12.3.4. Financial Overview
         12.3.5. Strategic Overview
   12.4.  Sanofi S.A
         12.4.1. Company Overview
         12.4.2. Product Portfolio
         12.4.3. SWOT Analysis
         12.4.4. Financial Overview
         12.4.5. Strategic Overview
   12.5. Bayer AG
         12.5.1. Company Overview
         12.5.2. Product Portfolio
         12.5.3. SWOT Analysis
         12.5.4. Financial Overview
         12.5.5. Strategic Overview          
   12.6. Novartis
         12.6.1. Company Overview
         12.6.2. Product Portfolio
         12.6.3. SWOT Analysis
         12.6.4. Financial Overview
         12.6.5. Strategic Overview      
   12.7. Elekta
         12.7.1. Company Overview
         12.7.2. Product Portfolio
         12.7.3. SWOT Analysis
         12.7.4. Financial Overview
         12.7.5. Strategic Overview
   12.8. Theragenics
         12.8.1. Company Overview
         12.8.2. Product Portfolio
         12.8.3. SWOT Analysis
         12.8.4. Financial Overview
         12.8.5. Strategic Overview
   12.9. Pfizer Inc.
         12.9.1. Company Overview
         12.9.2. Product Portfolio
         12.9.3. SWOT Analysis
         12.9.4. Financial Overview
         12.9.5. Strategic Overview
   12.10. Abbot Laboratories
         12.10.1. Company Overview
         12.10.2. Product Portfolio
         12.10.3. SWOT Analysis
         12.10.4. Financial Overview
         12.10.5. Strategic Overview
   12.11. Genentech
         12.11.1. Company Overview
         12.11.2. Product Portfolio
         12.11.3. SWOT Analysis
         12.11.4. Financial Overview
         12.11.5. Strategic Overview
   12.12. Roche
         12.12.1. Company Overview
         12.12.2. Product Portfolio
         12.12.3. SWOT Analysis
         12.12.4. Financial Overview
         12.12.5. Strategic Overview
   12.13. AbbVie
         12.13.1. Company Overview
         12.13.2. Product Portfolio
         12.13.3. SWOT Analysis
         12.13.4. Financial Overview
         12.13.5. Strategic Overview
   12.14. Varian Medical Systems
         12.14.1. Company Overview
         12.14.2. Product Portfolio
         12.14.3. SWOT Analysis
         12.14.4. Financial Overview
         12.14.5. Strategic Overview
 
13. Pre and Post COVID-19 Impact
   13.1. Positive influence on the healthcare industry
   13.2. The financial disruption of the manufacturing sector
   13.3. Impact of COVID-19 on emerging companies
   13.4. Significant mandates in the healthcare regulations initiated by administrations
   13.5. The overall economic slowdown of the developing and developed nations

14. FutureWise SME Key Takeaway Points for Client

Tables

Figures